Voyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Analysts at Wedbush

Analysts at Wedbush began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Friday. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 90.31% from the stock’s current price.

VYGR has been the topic of several other research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $17.50.

Voyager Therapeutics Stock Performance

VYGR opened at $5.78 on Friday. The stock has a market capitalization of $315.76 million, a P/E ratio of 8.14 and a beta of 0.89. The company’s 50-day simple moving average is $6.50 and its two-hundred day simple moving average is $7.32. Voyager Therapeutics has a 52-week low of $5.19 and a 52-week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the prior year, the business earned ($0.59) EPS. Research analysts forecast that Voyager Therapeutics will post -1.03 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its holdings in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares in the last quarter. Intech Investment Management LLC bought a new position in Voyager Therapeutics in the third quarter worth about $74,000. SG Americas Securities LLC bought a new position in Voyager Therapeutics in the second quarter worth about $85,000. Victory Capital Management Inc. raised its holdings in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in Voyager Therapeutics in the second quarter worth about $128,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.